CRNO B — Cereno Scientific AB Share News
0.000.00%
Last trade - 00:00- SEK1.50bn
- SEK1.60bn
Brief: Cereno Scientific Secures SEK 100 Mln Through Loan Financing, Conversion To Advance HDAC Inhibitors
Brief: Cereno Scientific Q1 Loss After Financial Items Widens TO SEK 25 Mln
Brief: Cereno Scientific Extends Patent Protection For Drug Candidate CS1 In U.S.
Brief: Cereno Scientific Lead Candidate CS1 Trial Meets Primary Endpoint
Brief: Cereno Scientific Q4 Adjusted EPS Is SEK -0.14
Brief: Cereno Scientific Drug Candidate Cs014 Completes First Part Of Phase I Trial
Brief: Cereno Scientific Q3 Loss After Financial Items SEK 22.7 Mln
Brief: Cereno Scientific Signs Agreement With Fluidda
Brief: Cereno Scientific Announces Positive Topline Results Of Phase Iia Trial With Lead Candidate Cs1 In Pulmonary Arterial Hypertension
Brief: Cereno Scientific - New Preclinical Data Show Dose Dependent Positive Impact On Reversal Of Pulmonary Vascular Remodeling By Novel HDACi CS014
Brief: Cereno Scientific Expands Patent Protection For CS585 In China
Brief: Cereno Scientific Granted OMPD For CS1 In Rare Disease Pulmonary Arterial Hypertension
Brief: Cereno Scientific Q2 Loss After Financial Items Widens To SEK 21.2 Mln
Brief: Cereno Scientific Expands Patent Protection For PAH Drug Candidate
Brief: Cereno Scientific Extends Financial Runway By Extending Loan Maturity Date Until March 31, 2026
Brief: Cereno Scientific Expands Patent Protection For PAH Drug Candidate CS1:s Second, Third Patent Family
Brief: Cereno Scientific's BoD, Executive Management Enter Into Lock-Up Agreements
Brief: Cereno Scientific Says Preclinical Data For Drug Candidate Cs585 Showing High Selectivity For The IP Receptor
Brief: Cereno Scientific Starts Collaboration With PVRI